aTyr Pharma announced fourth quarter and full year 2025 results, reporting a net loss of $74.1 million for the year ended December 31, 2025. The company ended 2025 with $80.9 million in cash and investments and scheduled a Type C meeting with the FDA for mid-April 2026 to review the Phase 3 EFZO-FIT study results.
Key takeaways
Phase 3 EFZO-FIT study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.
Company scheduled to meet with the FDA in mid-April 2026 to review Phase 3 results and determine the path forward for efzofitimod in pulmonary sarcoidosis.
Phase 2 EFZO-CONNECT study in SSc-ILD is on track to complete enrollment in the first half of 2026.
Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.
Net loss for the year ended December 31, 2025 was $74.1 million, or $0.80 per share, compared to $64.0 million, or $0.86 per share, for the prior year.